Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

被引：409

作者：

Targher, Giovanni ^{[1
]}

Tilg, Herbert ^{[2
]}

Byrne, Christopher D. ^{[3
,4
]}

机构：

[1] Azienda Osped Univ Integrata Verona, Dept Med, Sect Endocrinol Diabet & Metab, I-37126 Verona, Italy

[2] Innsbruck Med Univ, Dept Internal Med Gastroenterol Hepatol Endocrino, Innsbruck, Austria

[3] Univ Southampton, Fac Med, Dept Nutr & Metab, Southampton, Hants, England

[4] Univ Hosp Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England

来源：

LANCET GASTROENTEROLOGY & HEPATOLOGY | 2021年 / 6卷 / 07期

关键词：

ARTERY CALCIUM SCORE; LONG-TERM PROGNOSIS; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; ASYMPTOMATIC PATIENTS; ADVANCED FIBROSIS; RISK; NAFLD; ASSOCIATION; STEATOHEPATITIS;

D O I：

10.1016/S2468-1253(21)00020-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, the predominant cause of mortality in people with NAFLD), chronic kidney disease, and some types of extrahepatic malignancies. The magnitude of this risk parallels the severity of NAFLD ( especially the stage of liver fibrosis). There are probably multiple underlying mechanisms by which NAFLD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications. Addressing the growing burden of NAFLD will require setting up a multidisciplinary working group and framework to progress and embrace novel collaborative ways of working to deliver holistic, person-centred care and management of people with NAFLD.

引用

页码：S78 / S88

页数：11

共 93 条

[1] 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial [J].